Page 2 - Pharma Stocks

Sun Pharma Q2 preview: Profit may dip YoY despite revenue growth; details

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period

Ajanta Pharma offers growth potential amid US generic challenges: Nuvama

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

Motilal Oswal initiates with 'Buy' on Rubicon Research; check target

Motilal Oswal has initiated coverage on Rubicon Research, a pharmaceutical manufacturing company, with a 'Buy' rating

Cipla Q2 revenue grows, margins squeeze; analysts decode stock strategy

In the Q2FY26, Cipla reported consolidated revenue from operations of ₹7,589 crore, up 8 per cent year-on-year (Y-o-Y) from ₹7,051 crore in the year-ago period

Dr Reddy's plunges 6%, hits 5-month low; why pharma stock under pressure?

Dr Reddy's Laboratories has received a Notice of Non-Compliance from Pharmaceutical Drugs Directorate, Canada, regarding its Abbreviated New Drug Submission for Semaglutide Injection.

Cipla Q2 preview: Pharma major may see stable qtr; check key estimates here

Cipla is expected to report a profit after tax (PAT) of ₹1,361.6 crore for the September 2025 quarter, against ₹1,302.5 crore in Q2FY25

Sigachi Industries stock falls 4% after weak Q2; net profit down 50% YoY

Sigachi Industries reported revenue from operations of ₹113 crore in Q2FY26, down 19 per cent from ₹139.5 crore in the year-ago period

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period

Cipla rallies 4%, hits 52-week high; Choice Broking sees more upside

Cipla stock outlook: A decisive breakout above ₹1,580 could trigger further upward momentum, paving the way towards the ₹1,770-₹1,850 target range in the medium term, said Choice Broking.

Divis Labs rallies 13% in 1 week; What's driving pharma stock?

Divis stock gained 2% in Monday's intra-day deals. Reports suggest the company is well positioned to benefit from emerging trends across both API and CDMO domains through innovation and capex.

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Lupin shares jump 4% on new Florida manufacturing facility plan

Lupin said the project aims to boost medicine security, diversify supply chains, and reinforce its position as a global leader in respiratory therapies

Rubicon Research IPO opens Oct 9; key risks, strengths you must know

Rubicon Research IPO is available at a price band of ₹461-485 per share, with a lot size of 30 shares

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Asia stocks slide as Trump slaps new pharma tariffs, Fed cut bets recede

Shares of pharmaceutical companies across Asia tumbled in the aftermath, with Japan's Topix pharmaceutical index last down 1.2 per cent, while Hong Kong-listed innovative drug index fell 2 per cent

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Stocks to Watch today, Sept 26: Pharma, IT, auto, Polycab, Rites, Eternal

Stocks to Watch today, September 26, 2025: From Pharma, auto to Polycab, here is a list of stocks that will be in focus